Pfizer Korea Defends Reported Market Share Decline of Novarsc

Published: 2005-01-11 06:58:00

Updated: 2005-01-11 06:58:00

Pfizer Korea defends its position on the reported sharp decline in the domestic market share of Novarsc, by stating that the individual claims on the substitution rates of the original product made by its competing generic makers are not fully representing the market trend as a whole.

The comp...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK